|
1
|
Ostrom QT, Cioffi G, Gittleman H, Patil N,
Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system Tumors
Diagnosed in the United States in 2012–2016. Neuro Oncol. 21 (Suppl
5):v1–v100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burnet NG, Jefferies SJ, Benson RJ, Hunt
DP and Treasure FP: Years of life lost (YLL) from cancer is an
important measure of population burden- and should be considered
when allocating research funds. Br J Cancer. 92:241–245. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Majewska P, Ioannidis S, Raza MH, Tanna N,
Bulbeck H and Williams M: Postprogression survival in patients with
glioblastoma treated with concurrent chemoradiotherapy: A routine
care cohort study. CNS Oncol. 6:307–313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, Van Den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van den Bent MJ, Tesileanu CMS, Wick W,
Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak
AK, Baurain JF, et al: Adjuvant and concurrent temozolomide for
1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study
26053-22054): Second interim analysis of a randomised, open-label,
phase 3 study. Lancet Oncol. 22:813–823. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Central Nervous System Cancers-NCCN
Guidelines, . https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf12–Apr.
2023
|
|
7
|
Gallo C, Buonerba C, Di Lorenzo G, Romeo
V, De Placido S and Marinelli A: Can high-dose fotemustine reverse
MGMT resistance in glioblastoma multiforme? J Neurooncol.
100:311–319. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei W, Chen X, Ma X, Wang D and Guo Z: The
efficacy and safety of various dose-dense regimens of temozolomide
for recurrent high-grade glioma: A systematic review with
meta-analysis. J Neurooncol. 125:339–349. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiapaer S, Furuta T, Tanaka S, Kitabayashi
T and Nakada M: Potential strategies overcoming the temozolomide
resistance for glioblastoma. Neurol Med Chir (Tokyo). 58:405–421.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Malkki H: Trial Watch: Glioblastoma
vaccine therapy disappointment in Phase III trial. Nat Rev Neurol.
12:1902016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Xing D, Zhao M, Wang J and Yang Y:
The role of a single angiogenesis inhibitor in the treatment of
recurrent Glioblastoma multiforme: A Meta-analysis and systematic
review. PLoS One. 11:e01521702016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Birzu C, French P, Caccese M, Cerretti G,
Idbaih A, Zagonel V and Lombardi G: Recurrent Glioblastoma: From
molecular landscape to new treatment perspectives. Cancers (Basel).
13:472020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beauchesne P: Fotemustine: A
third-generation nitrosourea for the treatment of recurrent
malignant gliomas. Cancers (Basel). 4:77–87. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Addeo R, De Santi MS, Del Prete S and
Caraglia M: Fotemustine and recurrent glioblastoma: Possible new
opportunities for an old drug. Cancer Chemother Pharmacol.
64:863–866. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Addeo R, Caraglia M, De Santi MS, Montella
L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V,
Genovese M, et al: A new schedule of fotemustine in
temozolomide-pretreated patients with relapsing glioblastoma. J
Neurooncol. 102:417–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Frenay M, Giroux B, Khoury S, Derlon JM
and Namer M: Phase II study of fotemustine in recurrent
supratentorial malignant gliomas. Eur J Cancer. 27:852–856. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fabrini MG, Silvano G, Lolli I, Perrone F,
Marsella A, Scotti V and Cionini L: A multi-institutional phase II
study on second-line Fotemustine chemotherapy in recurrent
glioblastoma. J Neurooncol. 92:79–86. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De Felice F, Bulzonetti N, Musio D, D'Elia
A, Salvati M and Tombolini V: Low-dose fotemustine as second-line
chemotherapy for recurrent glioblastoma multiforme. Anticancer Res.
33:4013–4016. 2013.PubMed/NCBI
|
|
19
|
Lombardi G, Farina P, Della Puppa A,
Cecchin D, Pambuku A, Bellu L and Zagonel V: An overview of
fotemustine in high-grade gliomas: From single agent to association
with bevacizumab. Biomed Res Int. 2014:6985422014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Addeo R, Lamberti G, Simonetti G, Iodice
P, Marinelli A, Montella L, Cappabianca S, Gaviani P, Caraglia M,
Prete SD and Silvani A: Biweekly fotemustine schedule for recurrent
glioblastoma in the elderly: Activity and toxicity assessment of a
multicenter study. CNS Oncol. 8:CNS322019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weller M, van den Bent M, Hopkins K, Tonn
JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D,
Henriksson R, Balana C, et al: EANO guideline for the diagnosis and
treatment of anaplastic gliomas and glioblastoma. Lancet Oncol.
15:e395–e403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leone A, Colamaria A, Fochi NP, Sacco M,
Landriscina M, Parbonetti G, de Notaris M, Coppola G, De Santis E,
Giordano G and Carbone F: Recurrent Glioblastoma treatment: State
of the art and future perspectives in the precision medicine era.
Biomedicines. 10:19272022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yushkevich PA, Piven J, Hazlett HC, Smith
RG, Ho S, Gee JC and Gerig G: User-guided 3D active contour
segmentation of anatomical structures: Significantly improved
efficiency and reliability. Neuroimage. 31:1116–1128. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fedorov A, Beichel R, Kalpathy-Cramer J,
Finet J, Fillion-Robin JC, Pujol S, Bauer C, Jennings D, Fennessy
F, Sonka M, et al: 3D slicer as an image computing platform for the
quantitative imaging network. Magn Reson Imaging. 30:1323–1341.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
WHO Classification of Tumours Editorial
Board, . World Health Organization classification of tumours of the
central nervous system. 5th edition. International Agency for
Research on Cancer; Lyon: 2021
|
|
26
|
Wen PY, Macdonald DR, Reardon DA,
Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert
MR, Lassman AB, et al: Updated response assessment criteria for
high-grade gliomas: Response assessment in Neuro-oncology working
group. J Clin Oncol. 28:1963–1972. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
De Rossi A, Rossi L, Laudisi A, Sini V,
Toppo L, Marchesi F, Tortorelli G, Leti M, Turriziani M, Aquino A,
et al: Focus on fotemustine. J Exp Clin Cancer Res. 25:461–468.
2006.PubMed/NCBI
|
|
28
|
Marinelli A, Lamberti G, Cerbone L, Cordua
N, Buonerba C, Peluso G, Di Lorenzo G and De Placido S: High-dose
fotemustine in temozolomide-pretreated glioblastoma multiforme
patients. Medicine (Baltimore). 97:e112542018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pérez-Segura P, Manneh R, Ceballos I,
García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela
M, et al: GEINOFOTE: Efficacy and safety of fotemustine in patients
with high-grade recurrent gliomas and poor performance status. Clin
Transl Oncol. 18:805–812. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Prelaj A, Rebuzzi S, Grassi M, Salvati M,
D'Elia A, Buttarelli F, Ferrara C, Tomao S and Bianco V:
Non-conventional fotemustine schedule as second-line treatment in
recurrent malignant gliomas: Survival across disease and treatment
subgroup analysis and review of the literature. Mol Clin Oncol.
10:58–66. 2018.PubMed/NCBI
|
|
31
|
Scoccianti S, Detti B, Sardaro A, Iannalfi
A, Meattini I, Leonulli BG, Borghesi S, Martinelli F, Bordi L,
Ammannati F and Biti G: Second-line chemotherapy with fotemustine
in temozolomide-pretreated patients with relapsing glioblastoma: A
single institution experience. Anticancer Drugs. 19:613–620. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kono K, Inoue Y, Nakayama K, Shakudo M,
Morino M, Ohata K, Wakasa K and Yamada R: The role of
diffusion-weighted imaging in patients with brain tumors. AJNR Am J
Neuroradiol. 22:1081–1088. 2001.PubMed/NCBI
|
|
33
|
Leao DJ, Craig PG, Godoy LF, Leite CC and
Policeni B: Response assessment in Neuro-oncology criteria for
gliomas: Practical approach using conventional and advanced
techniques. Am J Neuroradiol. 41:10–20. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hsu CH, Lober RM, Li MD, Partap S, Murphy
PA, Barnes PD, Fisher PG and Yeom KW: Decreased tumor apparent
diffusion coefficient correlates with objective response of
pediatric low-grade glioma to bevacizumab. J Neurooncol.
122:491–496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Galla N, Chiang G, Chakraborty S, Singh R,
John Tsiouris A, Boockvar J and Kovanlikaya I: Apparent diffusion
coefficient changes predict survival after intra-arterial
bevacizumab treatment in recurrent glioblastoma. Neuroradiology.
59:499–505. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu
P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, et al: Apparent
diffusion coefficient histogram analysis stratifies
progression-free and overall survival in patients with recurrent
GBM treated with bevacizumab: A multi-center study. J Neurooncol.
108:491–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sener RN: Diffusion MRI: Apparent
diffusion coefficient (ADC) values in the normal brain and a
classification of brain disorders based on ADC values. Comput Med
Imaging Graph. 25:299–326. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kamali A, Gandhi A, Nunez LC, Lugo AE,
Arevalo-Espejo O, Zhu JJ, Esquenazi-Levy Y, Zhang X and Riascos RF:
The role of apparent diffusion coefficient values in Glioblastoma:
Differentiating tumor progression versus treatment-related changes.
J Comput Assist Tomogr. 46:923–928. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fabi A, Metro G, Russillo M, Vidiri A,
Carapella CM, Maschio M, Cognetti F, Jandolo B, Mirri MA, Sperduti
I, et al: Treatment of recurrent malignant gliomas with fotemustine
monotherapy: Impact of dose and correlation with MGMT promoter
methylation. BMC Cancer. 9:1012009. View Article : Google Scholar : PubMed/NCBI
|
